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Abstract
The COVID-19 outbreak has infected millions of people worldwide, but no vaccine has been discovered to combat it
efﬁciently. This research aims to design a multi-epitope vaccine using highly efﬁcient B- and T-cell epitopes from the
SARS-CoV-2 Surabaya isolate through a viroinformatic approach. First, the putative epitopes were linked together to
develop tertiary structures and then docked with toll-like receptor 4 (TLR-4) that demonstrated a robust interaction with
a low eigenvalue of 4.816138 e¡06. Furthermore, the structure's high immunogenic response was observed and successfully cloned into the expression vector pET28a (þ). This implies that the designed vaccine can prove effective in
combating SARS-CoV-2.
Keywords: Bioinformatics, SARS-CoV-2, Public health, MHC-I and MHC-II, Multi-epitope vaccine

1. Introduction

A

t the end of December 2019, a few people
from Wuhan, China, were reported to have
pneumonia symptoms. Upon examination, the
SARS-CoV-2 virus was revealed as the causative
agent of the infection [1,2]. The novel coronavirus
disease (COVID-19) pandemic was designated a
public health emergency by the World Health Organization (WHO) in January 2020. It has been
estimated that since 30 December 2019, over 218.94
million people have been infected with COVID-19.

Moreover, about 4.53 million people have died [3].
SARS-CoV-2 has a novel characteristic of spreading
rapidly since many of its patients remain asymptomatic [4,5], and diagnostic methods take time [6,7].
The genome of SARS-CoV-2, like those of other
coronaviruses, encodes for a variety of structural
proteins. In the genome, the membrane “M,” the
nucleocapsid “N,” the spike “S,” and the envelope
“E" proteins are found as structural proteins.
Additionally, non-structural proteins such as
ORF1ab, ORF6, ORF3a, ORF8, ORF7a, and ORF10
are also evident [8]. The aminoacids-based genomic
similarity was 76% among both SARS-CoV and
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SARS-CoV-2 [9,10]. Owing to the high degree of
sequence similarity, we can use primary data of
SARS-CoV on protective immune responses for
developing a SARS-CoV-2 vaccine [11e14]. Cellular
and humoral responses are critical host defenses
against SARS-CoV. Experimentally, antibodies
developed against the “S" and “N" proteins were
reported to protect mice from the pathogenicity of
SARS-CoV infection. Moreover, identical antibodies
were discovered in SARS-CoV-2 and SARS-CoVaffected people [15e20]. On the other hand, antibody responses to the S protein were undetectable
six years after recovery [21]. Furthermore, stronger
antibody titers against the virus infection have been
identiﬁed in more severe clinical cases of viral
infection, implying that a strong antibody response
alone may not be enough to suppress SARS-CoV
and SARS-CoV-2 infections [22e25]. Due to the high
demand for safe and effective therapies against
SARS-CoV-2 [26e28]. Undoubtedly, any vaccinebased measures could be highly beneﬁcial in the
event of outbreaks or seasonal re-emergence,
largely dependent on long-term protective evolution. Given their genetic similarities, recent success
in developing vaccines against “SARS-CoV-100 and
“MERS-CoV” might be a signiﬁcant feature in
designing a vaccine against SARS-CoV-2 [29e33]. In
an outbreak crisis, traditional vaccination techniques based on laboratory trials could not address
the immediate needs; therefore, several therapeutic
substances are being evaluated [34e37]. A bioinformatics study is a powerful tool for sorting, organizing, and processing enormous amounts of data
from several research studies to build a broad
immunology platform in a short period. Due to the
availability of the virus genome and protein sequences, in silico analysis might be incorporated to
anticipate the reported epitopes and virus features,
considerably speeding up vaccine development
[38e42]. The current study aimed to predict B- and
T-cell epitopes from the SARS-CoV-2 M, N, and S
proteins and design a multi-epitope immunogenic
SARS-CoV's-2 subunit vaccine candidate using
bioinformatic techniques Fig. 1.

2. Material and methods
2.1. Ethical issues
Ethical approval for the current study was obtained from the Institutional Review Board of the Dr
Soetomo General Hospital, Surabaya under IRB
No.IRB00008635. The Ethical Clearance from the
same body was additionally obtained under No.
0099/LOE/301.4.2/VIII/2020.

2.2. Retrieval of the whole genome sequence and
translation into amino acids
The SARS-CoV-2 Surabaya isolate of the Research
Center for Vaccine Technology and Development,
Institute of Tropical Diseases (RCVTD-ITD), under
Accession No 1366505, was retrieved from the database of GISAID EpiCoV: (“https://www.gisaid.org/")
for the formulation of a putative SARS-CoV-2 vaccine. The Amino acid (protein) sequence was
deduced from the retrieved whole genome sequence
(RNA) sequences, using the ExPaSy tool: (http://
expasy.org/tools/dna.html).
Protein
segments
were identiﬁed using the NCBI's (National Center
for Biotechnology Information) Protein BLAST
[43,44].
2.3. B-cell and T-cell epitopes
B-cell epitopes are particular antigen region that
interacts strongly with B lymphocytes. As a result,
B-cells developed antigen-speciﬁc antibodies and
memory cells. The N, M, and S protein segments
were fed to the “Immune Epitope Database” (IEDB)
webserver (https://tools.iedb.org/bcell/) for prediction of the linear B-cell epitopes using the default
criteria [45,46].
MHC, e.g., (Major histocompatibility complex)
molecules are expressed on the cell surface and
deliver peptides to T cells, making them essential in
forming T-cell immune responses. MHC molecules
are divided into two types: MHC Class-I and MHC
Class-II. Furthermore, the N, M, and S protein segments were loaded into the IEDB's MHC-Class-I and
MHC-Class-II binding prediction-free online server:
(http://tools.iedb.org/mhc/n) for T-cell epitope prediction. We employed multiple approaches accessible on the server for T-cell prediction, including the
MHC-NP net CTLpan1.1 web server [47,48] and the
Rank PEP web server. However, we utilized the
IEBD-recommended 09.2020 (NetMHCpan EL 4.1)
results. The T-cell epitope length for humans was
speciﬁed as 9-mer and 15-mer for MHC Class-I and
MHC Class-II, respectively. HLA (Human Leukocyte
Antigen) molecules on the cell surface give peptides
that govern the interactions between T-cells and
antigen-presenting cells, essential for adaptive immunity. Because there is a varied array of antigens
has been discovered a high rate of recognition by the
various HLA-molecules in the population, as previously described [49]. HLA-A*01, A* 26, A*03, A*11,
A* 02, A* 24, A*32, and HLA-B*35, 27, 51 were utilized in this study for MHC-I. In contrast, HLADRB1*03, 07, 15, 13, 04, 11 were used for MHC-II.
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Peptides with a percentile rank of less or equal to one
(1) were designated as sequence epitopes [50].
2.4. Prediction of non-toxicity, non-allergenicity,
and antigenicity of B-cell and T-cell epitopes
The predicted epitopes' antigenicity was tested
through the online web server VaxiJen-v2.0 (https://
www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.
html), by applying the default-threshold [51]. This
web server was designed to categorize antigen
exclusively based on physicochemical characteristics of protein rather than sequence alignment. Allergy is a condition of hypersensitivity to generally
harmless items like medicines. Allergens are minute
antigens that elicit an IgE antibodies response in
most people. Subsequently, in the current study, we
fed our predicted epitopes into the AllerTOP-v.2.0,
web: (https://www.ddg-pharmfac.net/AllerTOP/):
keeping settings on default [52,53]. It is an alignment-free online web that predicts allergy-free
epitopes based on the physicochemical features of
proteins. Moreover, to assess the toxicity risk of
predicted epitopes, these epitopes were pasted into
the “ToxinPred” web-tool: (https://webs.iiitd.edu.in/
raghava/toxinpred/multi submit.php-) [53,54]. In
the construction of vaccines, conserved epitopes
give more comprehensive protection against multistrains than epitopes chosen from a diverse range of
genomic regions. Therefore, the conservancy of Bcell epitopes was analyzed using the ConservancyAnalysis tool in the IEBD sever [55].
2.5. Analyses of population coverage and epitope
conservation
Population coverage is an essential factor in vaccine
development. It is more affected by distinct HLAtypes present in different frequencies at different
ethnicities than the MHC-polymorphism. The universal coverage of interacting epitopes of MHC Class-I
and MHC Class-II alleles was carried out using the
IEBD Population-Coverage server: (http://tools.iedb.
org/population/-). Because of divergence in MHCHLA allele distribution around the globe, the population-coverage of Homo-sapiens MHC Class-I and
MHC Class-II interacting molecules was conducted.
Moreover, the conservancy of the predicted epitopes
was also tested using the IEDB Conservancy-Analysis
tool [56].
2.6. Construction of multi-epitope subunit vaccine
A multi-epitope subunit vaccine was developed
utilizing T-cell (MHC-I & MHC-II) and B-cell
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epitopes. For the development of the vaccine, the
50S ribosomal protein L7/L12 was employed as an
adjuvant. In addition, EAAAK linkers were also
utilized to connect the adjuvant with the B-cell
epitope. In contrast, GPGPG (Gly-Pro-Gly-Pro-Gly)
and AAY (Ala-Ala-Tyr) linkers connected the B-cell
with the MHC Class-I and MHC Class-1 with MHC
Class-II epitopes, respectively. Moreover, there
were overlapping sections in the B-cell; therefore,
MHC Class-I and MHC Class-II were merged to
eliminate overlap [56].
2.7. Physio-chemical analysis of multi-epitope
subunit construct
To evaluate the physicochemical characteristics
of our engineered subunit vaccine, we used the
ExPASY ProtParam program: (https://web.expasy.
org/protparam/). The service displayed theoretical-pI, amino acid composition, aliphatic-index,
instability-index, grand average of hydropathicity
(GRAVY), and molecular weight of the subunit
construct [57,58]. Furthermore, the solubility rate of
the subunit construct was determined using the
SOLpro web: (http://scratch.proteomics.ics.uci.
edu./) [56].
2.8. Structure analysis, reﬁnement, and validation
The subunit construct's secondary structure was
analyzed using the online Raptor X tool: (http://
raptorx.uchicago.edu/Structure Prediction/predict/)
[59]. The discovery of the essential role of the protein
components that constitute cellular proteomes is a
fundamental issue in modern biological sciences.
Therefore, developing a credible three-dimensional
(3D) atomic structure (model) of proteins is critical in
the current scenario. Thus the multi-epitope subunit's tertiary structure was generated using the
PHYRE2 protein fold recognition server [60]. The
tertiary structure was reﬁned using the GalaxyReﬁne: (http://galaxy.seoklab.org/cgi-bin/submit.cgi?
type¼REFINE), and the RAMPAGE: (http://mordred.
bioc.cam.ac.uk/rapper/rampage.php)
web-server
was used to validate the reﬁned 3D design [56].
2.9. Molecular docking and molecular dynamics
simulation (MDS)
The Cluspro.2.0 web server: (https://cluspro.org/
home.php) was used for proteineprotein docking in
order to determine the interaction between the reﬁned
subunit construct and the toll-like receptor 4's (TLR4's) ligand-binding domains (LBDs) [61]. Furthermore,
the surfactant protein A (1R13; carbohydrate
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recognition and neck domains) was used as a control
(C4) during the docking procedure with the TLR-4
receptor [62]. Furthermore, the docking results of
vaccine þ TLR-4 complex were evaluated for
proteineprotein interaction in the PDBsum website
(http://www.ebi.ac.uk/thornton-srv/databases/cgibin/pdbsum/GetPage.pl?pdbcode¼index.html) [63].
The iMODS web server (http://imods.chaconlab.org/)
was used to perform MDSs for critical component
constructs analysis by altering the formed complex's
force ﬁeld concerning various time intervals [64].

expasy.org/translate/). Segments from three types
of proteinsdS, M, and Ndwere selected from the
translated amino acid sequence. Conﬁrmatory
identiﬁcation was performed through the NCBI's
Protein BLAST tool. The chosen segments of proteins S, M, and N comprised 577 amino acids (start
position ¼ 7847), 235 amino acids (start
position ¼ 9572), and 222 amino acids (form
position ¼ 8805), respectively.

2.10. Codon optimization and in silico method for
peptide expression

A total of 34 B-cell epitopes with a threshold score
of 0.5 were predicted on N (epitopes ¼ 8), M
(epitopes ¼ 6), and S (epitopes ¼ 20) protein
sequence. In this study, the predicted linear epitopes
in BepiPred depicted the scoresdaverage: 0.454,
0.435, and 0.532; minimum: 0.185, 0.245, and 0.228;
maximum: 0.631, 0.668, and 0.709 on S, M, and N
proteins, respectively. The epitopes were fed to the
antigenicity prediction webserver: VaxiJen v2.0 using
a default value of the threshold and 7 B-cell antigenic
epitopes. The antigenic score for these potential Bcell candidates ranged from 0.4001 to 0.5859. These
predicted antigenic linear B-cell epitopes were
analyzed based on non-allergenicity and nontoxicity. Five B-cell epitopes were potential candidates for subunit vaccine formulation (Table 1). The
conservancy analysis of the ﬁnally antigenic, nontoxic, and non-allergenic B-cell epitopes was performed using the IEBD Conservancy Analysis tool;
the epitopes were highly conserved with 100%
coverage and identity conservation.

We used the following online weblink to predict the
host system for our designed vaccine: http://expsys.
weizmann.ac.il/expsysb/suggestES. The Java Codon
Adaptation Tool (JCat) was used for codon optimization, expression creation, and reverse translation [65].
The optimization process was utilized to create a
vaccine using Escherichia coli as the host organism
(strain K12). Rho-independent transcription, ribosomal binding sites, and restriction enzymatic cleavage sites were chosen as additional options [66]. The in
silico cloning was done with the E.coli pET-28 (þ)
expression vector. The nucleotide sequence was obtained from the Addgene vector database [67]. SnapGene v3.2.1 (GSL Biotech LLC, California, U.S.A.) was
used to clone poly-epitope subunit vaccines [66e68].
2.11. Immune stimulation of the engineered
construct
The host's immune response to the vaccine was
propagated through the online C-ImmSim web
server. This web server predicts the humoral and
cellular responses to a particular antigen. According
to the vaccine's preventative strategy, we planned
three consecutive doses on days 1, 28, and 56 [62].
The simulation steps were ﬁxed at 1050, and the
simulation volume was set to default [69].

3. Results
3.1. Retrieval of whole-genome sequence and
translation into amino acids
In the current study, the SARS-CoV-2 Surabaya
isolate of the RCVTD-ITD, with accession No.
1366505, was retrieved from the GISAID EpiCoV
database: (https://www.gisaid.org/) on 27 July 2021
for the construction of multi-epitope subunit vaccine. The whole-genome sequence was translated
into protein using the ExPASY tool (https://web.

3.2. Prediction and selection of B-cell epitopes

3.3. T-cell epitope prediction
3.3.1. MHC Class-I and MHC ClasseII binding
prediction proﬁle
This study applied T-cells of 9 (nine) mer and 15
(ﬁfteen) mer lengths for MHC Class-I and MHC
Class-II, respectively. The IEBD tool was used for
MHC-I and MHC-II binding prediction of N, M, and
S proteins. This study applied T-cells of 9 (nine) mer
and 15 (ﬁfteen) mer lengths for MHC Class-I and
MHC Class-II, respectively. Consequently, a total of
10,277 epitopes were found in MHC-I: S
(epitopes ¼ 5752), M (epitopes ¼ 2184), and N
(epitopes ¼ 2341). Moreover, a total of 4356 epitopes
were found in MHC-II: S (epitopes ¼ 2454), M
(epitopes ¼ 912), and N (epitopes ¼ 990). We chose
epitopes with high MCH-I and MCHeII binding
afﬁnity and a percentile rank of 1. Finally, seven
highly afﬁnitive, antigenic, non-allergenic, and nontoxic MHC-I epitopes (Table 2) and 10 MHC-II
epitopes with the same properties (Table 3) were
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Table 1. B-cell epitopes prediction in Surabaya isolate.
Protein name

Peptide

antigenic

Non allergic

Non toxic

Nucleocapsid

LKEQHCQKASTQKGAEAAVKPLLVP
LLLLEWLAMAVTKKSAAEASKKPRQKRTATKA
IDAYKTFPPTEPKKDKKKKADETQALPQRQ
KKQQTVTLLPAADLDDFSK QLQ QSMSSADS
AENSVAYSN
LPDPSKPSKRSF

Yes
Yes
Yes

Yes
Yes
Yes

yes
yes
yes

Yes
Yes

Yes
Yes

yes
yes

Spike

Table 2. Showing the highly effenitive MCH-I epitopes of Surabaya isolate.
Protein name

Peptide

Antigenicity

Non- allergic

Non-Toxic

Membrane

MACLVGLMW
ATSRTLSYY
SYFIASFRL
IPTNFTISV
KTFPPTEPK
AQFAPSASA
LLLEWLAMA

yes
yes
yes
yes
yes
yes
yes

yes
yes
yes
yes
yes
yes
yes

yes
yes
yes
yes
yes
yes
yes

Spike
Nucleocapsid

Table 3. Showing the highly effenitive MCH-II epitopes of Surabaya isolate.
Protein name

Peptide

Antigenicity

Non- allergic

Non-Toxic

Membrane

ANRNRFLYIIKLIFL
RNRFLYIIKLIFLWL
AIPTNFTISVTTEIL
IAIPTNFTISVTTEI
PTNFTISVTTEILPV
IPTNFTISVTTEILP
TNFTISVTTEILPVS
CSNLLLQYGSFCTQL
SNLLLQYGSFCTQLN
NLLLQYGSFCTQLNR

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

Spike

selected as potential candidates for the vaccine. The
antigenic score was predicted as 0.4821 and 0.4812
(minimum), and 0.8820 and 1.1691 (maximum) in
MHC-I and MHC-II, respectively, for those selected
as potential epitopes for vaccine construct.

82.17% for South Korea, and 80.01% for Japan.
Moreover, the predicted epitopes' conservancy was
assessed through the IEDB Conservancy Analysis
tool. It was found that all the epitopes were 100%
conserved.

3.4. Analyses of population coverage and epitope
conservation

3.5. Construction of multi-epitope subunit vaccine

The IEBD Population Coverage tool was used to
determine the global coverage of interacting epitopes of MHC-I and MHC-II alleles. There is a
divergence in MHC-HLA allele distribution around
the globe. Therefore, the population coverage of H.
sapiens MHC-I and MHC-II interacting molecules
was conducted. The following distribution was obtained: 92.06% for Europe, 90.71% for Oceania,
88.28% for North America, 84.66% for East Asia, and
83.77% for Southeast Asia (Table 4). Moreover,
country-wise coverage was found to be 91.98% for
the Philippines, 90.51% for England, 88.54% for
Saudi Arabia, 85.85% for Taiwan, 84.78% for France,

A multi-epitope subunit vaccination was developed using MHC-I, MHC-II, and B-cell epitopes.
Furthermore, the 50S ribosomal protein L7/L12 was
used as an adjuvant in the vaccine's development.
EAAAK linkers were used to link the L7/L12 (adjuvant) to the B-cell epitope. In contrast, GPGPG and
AAY linkers were used to link the B-cell to the
MHC-I and MHC-II epitopes, respectively. Moreover, there were overlapping sections in B-cell;
therefore, MHC-1 and MHCII also were merged to
eliminate overlap. In this multi-epitope construct, a
total of 7, 10, and 5 MHC-1, MHC-II, and linear Bcell epitopes, respectively, were used. The constructed multi-epitope subunit sequence had a
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Table 4. Predicted population coverage of the constructed vaccine worldwide.
population/area

Europe
Oceania
North America
East Asia
Southeast Asia
South Asia
Northeast Asia
West Indies

Class I

Class II

Class combined

coveragea

average_hitb

pc90c

coveragea

average_hitb

pc90c

coveragea

average_hitb

pc90c

83.92%
86.08%
77.43%
79.48%
78.11%
62.35%
75.02%
68.19%

1.19
1.13
1.03
1.06
1.0
0.79
0.96
0.9

0.62
0.72
0.44
0.49
0.46
0.27
0.4
0.31

50.62%
33.27%
48.06%
25.25%
25.83%
51.33%
26.62%
38.53%

2.04
0.89
1.87
0.87
0.84
2.16
0.94
1.43

0.41
0.3
0.39
0.27
0.27
0.41
0.27
0.33

92.06%
90.71%
88.28%
84.66%
83.77%
81.68%
81.67%
80.45%

3.23
2.02
2.9
1.94
1.84
2.95
1.9
2.33

1.08
1.02
0.85
0.65
0.62
0.55
0.55
0.51

molecular weight of 59974.20 Da based on 563 amino
acids.
3.6. Antigenicity, toxicity, and allergenicity
analysis of the subunit vaccine construct
The constructed subunit vaccine sequence was
subjected to the VaxiJen v 2.0 webserver to evaluate
the antigenicity, which was antigenic with and without
adjuvant. Then, the sequence was tested in Aller TOP
v.2.0 server, and it was found that the construct was
non-allergenic with and without adjuvant. The nontoxicity of the multi-epitope construct without adjuvant and of the adjuvant itself was tested. The score of
0.5059 was predicted with adjuvant, while the score
without adjuvant was 0.5433.
3.7. Physio-chemical and solubility characteristics
of multi-epitope subunit construct
The physical and chemical properties of the multiepitope construct were analyzed through the
ExPASY ProtParam web server. The current multiepitope subunit construct's molecular weight was
59.97420 kDa. The theoretical pI of protein was 8.69,
instability index (II) was 30.90, the aliphatic index
was 89.98, and GRAVY was 0.065. The solubility rate
was found to be 0.960121 when our construct was
analyzed through the SOLpro web server of
SCRATCH Protein Predictor.
3.8. Secondary structure of subunit construct
The secondary structure of the multi-epitope
construct was analyzed through the Raptor X tool to
determine the nature of the protein. This secondary
protein structure analysis revealed 32% helix, 11%
beta stands, and 56% coils. Moreover, a total of 62%,
19%, and 18% exposed, medium-exposed, and buried
contents, respectively, were found. In the current
protein structure, 39% of positions were in disordered
domains.

3.9. The tertiary structure of the subunit construct
In this study, the PHYRE2 protein fold recognition
server was used to develop the tertiary structure of
our multi-epitope subunit construct. The top predicted model was selected based on 100% conﬁdence and maximum coverage and identity from the
120 predicted models (Fig. 2).
3.10. Reﬁnement process for the tertiary structure
The projected 3D model of the multi-epitope
construct was submitted to the GalaxyReﬁne web
server, and ﬁve different reﬁned models were
found. In the current study, we selected Model 4 by
considering various parameters of reﬁnement:
MolProbity (2.147), RMSD (0.213), and GDT-HA
(1.0000) (Fig. 2). The current model-calculated clash
score was found to be 12.8, the poor rotamers score
was found to be 2.2, and the Ramachandran-favored
score was found to be 96.0%. In contrast, our initial
model showed a MolProbity score of 1.856, RMSD of
0.000, and GDT-HA of 1.0000. The initial modelcalculated clash score was found to be 13.3, the poor
rotamers score was found to be 1.1, and the Ramachandran-favored score was found to be 96.8%.
3.11. Validation of reﬁned 3D structure
The reﬁned structure was validated through the
RAMPAGE web server. The structural analysis was
performed, and the Ramachandran plot was developed for the protein structure. Before reﬁnement,
92.9% region was lying in the favorite region, 3.5%
in the additional allowed regions, and 2.7% structural region was found to be in the generously
allowed regions, as the reﬁnement process lowered
the critical errors of the 3D model. After reﬁnement,
the RAMPAGE-generated plot showed 96.5% residues in the favorite region, 2.7% in the additional
allowed region, 0% in the generously allowed region, and 0.9% in the disallowed regions (Fig. 3).
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Fig. 1. Graphical abstract of the study.

Fig. 2. Showing the 3D Structure of Multi-epitope Construct. (A) is depicting the tertiary structure predicted through the PHYRE-2 Web-Serwer and
(B) is reﬁned 3D-structure developed by Galaxy Reﬁne webserver.

3.12. Molecular docking
The molecular docking of the reﬁned vaccine
Model 4 and LBD of immune receptors TLR-3 and
TLR-4 (4G8A) were conducted through the
proteineprotein docking webserver Cluspro2.0.
This docking process predicted 30 different models
for the TLR-4 complex. Among all the models obtained after the analysis, we selected Model 0 of the
vaccine þ TLR-4 complex; it had the lowest docking

energy of 753.3 kcal/mol and 92 cluster members.
The PDBsum server revealed a highly stable
bonding afﬁnity between vaccine construct and
TLR-4. Our vaccine design linked TLR-4 potential
residues through 62 hydrogen bonds and 18 salt
bridges (Fig. 4). Moreover, the complex of
vaccine þ TLR-4_C4 (686.1 kcal/mol) had more
incredible energy than the vaccine þ TLR-4, clearly
indicating that our vaccine has a more robust
interaction than the control. The primary interacting
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Fig. 3. Showing the validation of 3D reﬁned structure of vaccine construct performed through RAMPAGE web server.

residues among vaccine, TLR-4, and vaccine þ TLR4_C4 are depicted in Fig. 4. It was found that the
vaccine attaches to the TLR-4 through the following
residues: Ser386:Ser386, Ala366:Asn365, Gly410:VaI411, Val411:VaI411, Val411:Gly410, Phe533:Phe533,
Asn365:Ala366,
His458:His458,
and
Gln507:Gln507. Meanwhile, the C4 control attaches
to the vaccine þ TLR-4 complex through the
following residues: Phe553:Phe553, His458:His458,

Ala366:Asn365,
Val411Gly410,
Val411:Val411,
Gly410:Val411, Gln507:Gln507, Asn365:Ala366, and
Ser386:386 (Fig. 5).
3.13. Molecular dynamics (MD) simulation
The vaccine þ TLR-4 complex was fed to the
iMODS web server. A normal mood analysis was
performed to assess the vaccine þ TLR-4 complex's
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Fig. 4. Showing the molecular docking results predicted by the Cluspro webserver (C) is depicting molecular docking of multi-epitope subunit vaccine
construct and receptor TLR4. (D) is showing the molecular docking of multi-epitope subunit vaccine and TLR4 complex with C4 control.

internal coordination. The complex's eigenvalue was
calculated to be 4.816138 e06 (Fig. 6 (J)). The
deformability results in individual deformation of
each residue, as seen by the chain hinges approach
(Fig. 6 (H)). In addition, there is a gradual decrease
of variance in each typical mood (Fig. 6 (K)). All of
these ﬁndings point out stable binding interactions
in the vaccine þ TLR-4 complex.

3.14. Codon optimization and in silico method for
peptide expression
JCat was used for codon optimization, expression
creation, and reverse translation. The optimization
process was utilized to create a vaccine using E. coli
as the host organism (strain K12). The length of the
optimization codon was 1689 bp nucleotides. The

Fig. 5. Showing the interaction results developed through the PDBsum webserver. (E) is depicting the interaction between TR4 and vaccine construct.
(F) is showing the TLR4þVaccine complex binding interaction of the residues with C4 control.
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Fig. 6. Showing the MDS results of vaccine and TLR4 docking complex. (G) is describing the mobility of vaccine and receptor directly towards eachother, (H) is describing high the deformability regions in B factor plot, (I) is depicting the similarity in NMA and PDB which means our actual results
of complex and the simulation results are same. (J) is showing the low Eigenvalue of our construct as Eigenvalue is directly proportional to the
deformability of construct, (K) is describing the individual and cumulative variance in red and green color respectively. (L) is depicting the covariance plot of our construct in which co- relationship, uncorrelation and anti- correlation are described with red, white and blue colors respectively,
(M) is describing the stiffness level of our construct in which dark gray color is showing the stiffer region.

codon adaptation index (CAI) was found to be 0.94
for the approved sequence. In contrast, guaninecytosine (GC) content was found to be 52.39. The in
silico cloning was done with the E. coli pET28a þ expression vector. The nucleotide sequence
was obtained from the Addgene vector database
Snap Gene v3.2.1 (GSL Biotech LLC, California,
U.S.A.) The codon sequence of the multi-epitope
subunit construct was inserted between the HindIII
(542) and NaeI (1472), which developed a clone of
4843 bp (Fig. 7).
3.15. Immune stimulation (IS) of the constructed
subunit vaccine
The host's immune response to the vaccine was
propagated through the online C-ImmSim web
server. The simulation steps were adjusted at one
thousand and ﬁfty (1050), and the simulation volume was ﬁxed at default. The IgM increase is the
indicator for the primary response. The secondary
and tertiary responses are characterized by a higher
level of B-cell population and high levels of

IgG1 þ IgG2, IgM, and IgG þ IgM. Furthermore, the
current study revealed cytokine and interleukin
production, which depicts the vaccine's efﬁciency in
triggering an immune response. TGF-, IFN-, and IL2 were also identiﬁed in signiﬁcant concentrations,
all of which are vital for co-stimulation of T-cell
activation (Fig. 8).

4. Discussion
COVID-19 has become one of the world's most
critical public health concerns. Thus, investing time
to develop efﬁcient preventive strategies is worth it.
Compared to traditionally adapted approaches used
in SARS-COV-2 vaccine designs, bioinformatics
techniques play a signiﬁcant role in easing and
speeding up the prediction of potential epitope
vaccines [41,60,70,71,72]. Although several studies
have used immunoinformatic approaches to
develop possible vaccines against SARS-CoV-2
[62,73e75], these in silico investigations for SARSCoV-2 targeted both non-structural and structural
proteins. Our study focused largely on structural
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Fig. 7. Showing the insertion of multiepitope vaccine in pET-28-a(þ) expression vector between HindIII and NaeI and found in results a colon of
4843bp.

proteins since they are promising for generating an
effective and safe immune response against SARSCoV-2. Furthermore, we focused on local Surabaya
isolates for vaccine development in this work, as
local viral vaccines are more effective and efﬁcient
against viral infections [76]. The three structural
proteins of the SARS-CoV-2 virus were identiﬁed to
form richly immunogenic epitopes that can trigger
cellular and humoral responses. Antigenic, nonallergenic, and non-toxic B- and T-cell epitopes
were created using the amino acid sequence of
1,366,505 from the Surabaya isolate. S, M, and N
proteins were identiﬁed in the amino acid sequence
of the SARS-CoV-2 Surabaya isolate, and B- and Tcells were produced for each of these proteins
individually [50]. The sequences of the N
(epitopes ¼ 8), M (epitopes ¼ 6), and S
(epitopes ¼ 20) proteins revealed a total of 34 B-cell
epitopes. The antigenicity, non-allergenicity, and
non-toxicity of these linear B-cell epitopes were
determined using the VaxiJen v2.0, Aller TOP v.2.0,
and ToxinPred servers respectively. We adopted

this method as described in an earlier study [56],
and 5 B-cell epitopes were identiﬁed as potential
candidates for subunit vaccine formulation (Table
2). In this investigation, we used 9-mer and 15-mer
T-cell lengths for MHC-I and MHC-II, respectively
[50]. The N, M, and S proteins were used to predict
MHC-I and MHCeII binding using the IEBD tool,
yielding a total of 10,277 MHC-I epitopes and 4356
MHC-II epitopes. We chose epitopes with high
MCH-I and MCHeII binding afﬁnity and a
percentile rank of 1 [50,56]. A total of seven highly
afﬁnitive, antigenic, non-allergenic, and non-toxic
MHC-I epitopes were chosen as possible vaccination candidates (Table 3), and 10 MHC-II epitopes
with the same properties were chosen (Table 4).
Once, B-cells were the only source for developing
a possible vaccine. B-cell responses are signiﬁcant
because they are responsible for producing antibody-based immunity. MHC-I and MHC-II T-cells
with HLA designs developed through bioinformatics are more faster and effective in clinical research
[77]. T-cells can trigger a signiﬁcant and cross-
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Fig. 8. Showing the IS (immune simulation) results of constructed multi-epitope vaccine. (N) is depicting the antigen antibody relationship as antigen
decreased the antibodies level increased also showing the increase in IgG level which is indicator for primary responses. (O) is describing the B-cell
population level increasement which indicates secondary and tertiary responses, (P) is depicting the TH-cell population level rise up, (Q) is showing
the TC-Cell population level, (R) is showing dendritic-cells which depicts the presence of antigenic peptides on the MHC-I and II, (S) is showing the
epithelial cell generation, (T) is describing the interleukins and cytokines concentration level.

reactive immunological response against the SARSCoV-2 infection. T-cell-produced immunity is longlasting [78]. MHC-I, MHC-II, and B-cell epitopes
were used to create a multi-epitope subunit vaccine.
In addition, in the development of the vaccine, the
50S ribosomal protein L7/L12 was employed as an
adjuvant, and EAAAK linkers were utilized to connect the L7/L12 (adjuvant) to the B-cell epitope;
moreover, GPGPG and AAY linkers were employed
to bind the B-cell to the MHC-I and MHC-II epitopes, respectively. Furthermore, there were overlapping sections in B-cell; MHC-I and MHC-II were
also merged to eliminate overlap [56]. A total of 7,
10, and 5 MHC-I, MHC-II, and linear B-cell epitopes, respectively, were employed in this multiepitope construct. The multi-epitope subunit
sequence constructed has a molecular weight of
59,974.20 Da based on 563 amino acids. The use of
adjuvant linkage with built vaccines improves the
construct's immunogenicity [79]. The design was
discovered to be antigenic and non-allergenic.

Vaccines, like other drugs, have the potential to
induce allergic responses. Mild vaccine reactions
are frequent, but sometimes they can lead to severe
consequences. It has been determined that the most
signiﬁcant barrier to vaccine development is allergenicity [80].
The IEBD Population Coverage tool was used to
determine the global coverage of interacting epitopes of MHC-I and MHC-II alleles. There is a
divergence in MHC-HLA allele distribution around
the globe; therefore, the population coverage of H.
sapiens MHC-I and MHC-II interacting molecules
was conducted, and the following distribution was
obtained: 92.06% for Europe, 90.71% for Oceania,
88.28% for North America, 84.66% for East Asia, and
83.77% for Southeast Asia. Our population coverage
of 92.06% is in line with the 92.51% coverage reported by Sadat et al. [50]. The vaccination must be
70% effective, and it must be 80% effective to primarily eradicate an epidemic without the need for
additional measures [81]. The physio-chemical
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characteristics of peptides signiﬁcantly impact their
immunogenicity, transportation, and stability [82].
The current multi-epitope subunit construct has a
molecular weight of 59.97420 kDa (59974.20 Da),
within the ideal range of 40e70 kDa. The lesser
molecular weight of the vaccine is believed to be
ideal because the puriﬁcation process of the vaccine
is easier for low molecular weight. The vaccine
protein's theoretical pI was discovered to be 8.69,
indicating that it is essential. The instability index
was determined to be 30.90; a value less than 40
indicates that the structure is more stable [83,84].
The structure's aliphatic index was 89.98, indicating
that our construct is thermostable [85]. Its GRAVY
was 0.065, indicating a hydrophobic protein [86].
The solubility rate was calculated to be 0.960121,
which meant high solubility, an essential indicator
that it can be puriﬁed easily and produced on a large
scale [87]. The secondary structure analysis revealed
that 32% of the proteins were a-helix, 11% were beta
stands, and 56% were coiled. Furthermore, a total of
62%, 19%, and 18% exposed, medium-exposed, and
buried contents, respectively, were discovered.
Disordered domains were identiﬁed in 39% of the
locations in the existing protein structure. For optimum molecular docking, it is necessary to reduce
3D model inaccuracy and develop a high-quality 3D
structure. The 3D structure was reﬁned using GalaxyReﬁne, and the required features of the structure
were developed. Additionally, RAMPAGE ﬁndings
clearly showed that all parameters were in accordance, suitable for vaccine production. Only those
3D structures with more than 90% of their residues
in the favored region are deemed excellent. The
proteineprotein docking webserver Cluspro2.0 was
used to molecularly dock a reﬁned vaccine model
with the LBD of the immune receptor TLR-4 (4G8A)
since TLR-4 of host immune cells can recognize the
viral protein of SARS-CoV-2, which is essential for
adaptive immunity [88]. The molecular docking
studies revealed stable interactions between the
multi-epitope subunit construct and the TLR-4
complex, with a 753.3 kcal/mol; this score is more
damaging than the control docking complex energy
score of 727.7 kcal/mol reported previously by
Safavi et al. [62]. The low energy score of docking is
necessary for the efﬁcient binding of vaccines with
TLRs [89]. The multi-epitope construct eigenvalue of
MDS was 4.816138 e06, and it climbed steadily in
each paradigm during the dynamics (Fig. 6). The
variance plot showed that the individual variance
decreased in each subsequent mode. These MDS
ﬁndings exhibit the overall stability of the current
vaccine construct þ TLR-4 complex [77].
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The immunological simulation of a multi-epitope
subunit construct demonstrated perfectly normal
immune response trends after multiple antigen exposures. The immunoreactivity of the subunit
construct was tested by expressing it in the host E.
coli K12 strain [56]. The server predicted higher Band T-cell levels after repeated antigen exposure for
a longer period. Increased levels of the antiviral
cytokines IFN and IL2 indicated the possibility of Thelper cell activation and, consequently, increased
Ig production, which supports the humoral immune
response [90]. Most importantly, the vaccine design
must be expressed in an appropriate E. coli strain, to
develop recombinant proteins [91,92]. With a CAI of
0.94 and a GC content of 52.39%, the codon optimization method demonstrated high expression in
E. coli K12. Finally, the multi-epitope subunit vaccine sequence was inserted into the pET-28a vector
to efﬁciently encode the constructed protein in E.
coli cells. The codon sequence of the multi-epitope
subunit construct was inserted between the HindIII
(542) and NaeI (1472), which developed a codon of
4843 bp (Fig. 5).
The current study results depicted strong cellular
and humoral responses computationally, conﬁrming previous ﬁndings that S and N proteins have
properties that elicit both cellular and humoral responses. N protein individually generates coronavirus-speciﬁc CD8 þ T lymphocytes, and SARSCoV-2 M protein is the most cellularly immunogenic protein [93e97]. Thus, these immunogenic
properties of the current structural protein vaccine
design suggest that the vaccine may be a better
choice for combating SARS-CoV-2 infection. Thus,
for the sake of public health, the study's ﬁndings
should be conﬁrmed as quickly as possible in the
laboratory and ﬁeld.

5. Conclusion
Effective drug development is a time-consuming
and expensive procedure; however, the only option
for halting the present COVID-19 epidemic is to
develop effective and timely vaccines. The use of
viroinformatic techniques will undoubtedly aid in
developing a rapid and effective SARS-CoV-2 vaccine. This study used various bio- and viroinformatic techniques to design a multi-epitope subunit
vaccination. The potentiality of the developed
construct was evaluated using immunoinformatics.
Thus, an excellent humoral and cellular response
was discovered. Furthermore, the engineered subunit construct was successfully colonized in the
expression vector pET-28 a (þ), demonstrating that
vaccine production on a large scale is feasible.
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Therefore, the designed construct's true potential
has to be validated in the lab and the ﬁeld on a
priority basis in the interest of public health.
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